UBS Group Reiterates GBX 1,790 Price Target for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline (LON:GSKGet Rating) has been given a GBX 1,790 ($22.81) price target by equities research analysts at UBS Group in a report released on Thursday, Borsen Zeitung reports. UBS Group’s price target suggests a potential downside of 0.22% from the stock’s current price.

Several other brokerages also recently weighed in on GSK. JPMorgan Chase & Co. set a GBX 1,740 ($22.18) target price on shares of GlaxoSmithKline in a research note on Monday. Barclays reaffirmed an “equal weight” rating and set a GBX 1,675 ($21.35) target price on shares of GlaxoSmithKline in a research note on Monday, April 11th. The Goldman Sachs Group set a GBX 2,000 ($25.49) target price on shares of GlaxoSmithKline in a research note on Friday, January 7th. Deutsche Bank Rese… set a GBX 1,600 ($20.39) target price on shares of GlaxoSmithKline in a research note on Friday, April 22nd. Finally, Citigroup reaffirmed a “neutral” rating and set a GBX 1,600 ($20.39) target price on shares of GlaxoSmithKline in a research note on Tuesday, January 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of GBX 1,697.86 ($21.64).

GlaxoSmithKline stock opened at GBX 1,794 ($22.87) on Thursday. GlaxoSmithKline has a 1 year low of GBX 1,319.60 ($16.82) and a 1 year high of GBX 1,812 ($23.09). The company’s 50 day simple moving average is GBX 1,641.12 and its 200-day simple moving average is GBX 1,594.85. The company has a market capitalization of £91.21 billion and a price-to-earnings ratio of 20.71. The company has a debt-to-equity ratio of 113.27, a quick ratio of 0.53 and a current ratio of 0.79.

In related news, insider Charles Bancroft bought 2,790 shares of the stock in a transaction dated Wednesday, March 23rd. The stock was acquired at an average price of GBX 2,114 ($26.94) per share, for a total transaction of £58,980.60 ($75,172.83). Also, insider Emma Walmsley sold 34,031 shares of the stock in a transaction on Monday, February 14th. The stock was sold at an average price of GBX 1,610 ($20.52), for a total transaction of £547,899.10 ($698,316.47).

GlaxoSmithKline Company Profile (Get Rating)

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.